Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ProKidney Corp. (PROK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PROK (1-star) is a SELL. SELL since 5 days. Profits (-34.34%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.4
1 Year Target Price $4.4
| 4 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.88% | Avg. Invested days 17 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.76B USD | Price to earnings Ratio - | 1Y Target Price 4.4 |
Price to earnings Ratio - | 1Y Target Price 4.4 | ||
Volume (30-day avg) 7 | Beta 1.46 | 52 Weeks Range 0.46 - 2.59 | Updated Date 06/29/2025 |
52 Weeks Range 0.46 - 2.59 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -17994.78% |
Management Effectiveness
Return on Assets (TTM) -28.29% | Return on Equity (TTM) -45.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -235865660 | Price to Sales(TTM) 5745.71 |
Enterprise Value -235865660 | Price to Sales(TTM) 5745.71 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 2.13 | Shares Outstanding 129536000 | Shares Floating 78160800 |
Shares Outstanding 129536000 | Shares Floating 78160800 | ||
Percent Insiders 30.05 | Percent Institutions 41.88 |
Analyst Ratings
Rating 3 | Target Price 4.4 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ProKidney Corp.
Company Overview
History and Background
ProKidney Corp., founded to develop cell therapies for chronic kidney disease (CKD), went public through a SPAC merger. Its focus is on regenerative medicine to slow or reverse kidney disease progression.
Core Business Areas
- Cell Therapy Development: Developing REN-001, a proprietary cell therapy for CKD, designed to protect and potentially restore kidney function.
Leadership and Structure
ProKidney has a management team with experience in cell therapy and nephrology. The organizational structure is focused on research, clinical development, and manufacturing of REN-001.
Top Products and Market Share
Key Offerings
- REN-001: REN-001 is a cell therapy in clinical trials for diabetic kidney disease (DKD) and other forms of CKD. There is currently no market share as the product is still in trials. Competitors include companies developing drugs to manage CKD complications (e.g., dialysis providers, pharmaceutical companies targeting blood pressure or anemia).
Market Dynamics
Industry Overview
The CKD treatment market is large and growing, driven by aging populations, diabetes, and hypertension. It is currently dominated by dialysis and supportive care, with unmet needs for disease-modifying therapies.
Positioning
ProKidney aims to disrupt the CKD treatment paradigm with a regenerative cell therapy. It is positioned as a potential first-in-class treatment to slow or reverse disease progression.
Total Addressable Market (TAM)
The estimated TAM for CKD treatments is significant, potentially exceeding $100 billion annually. ProKidney is positioned to capture a portion of this market if REN-001 proves effective and gains regulatory approval.
Upturn SWOT Analysis
Strengths
- First-in-class regenerative cell therapy approach
- Proprietary technology platform
- Experienced management team
- Potential to address a large unmet medical need
Weaknesses
- Clinical trial risk
- Regulatory approval risk
- Manufacturing complexity
- High development costs
- Relatively small company
Opportunities
- Positive clinical trial results
- Strategic partnerships with pharmaceutical companies
- Expansion of REN-001 to other kidney diseases
- Regulatory fast-track designations
- Increasing prevalence of CKD
Threats
- Failure of clinical trials
- Regulatory delays or rejection
- Competition from other CKD therapies
- Adverse events associated with REN-001
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- GILD
- VRTX
- LLY
- NVO
Competitive Landscape
ProKidney's advantage lies in its regenerative cell therapy approach, which differentiates it from companies focused on managing CKD symptoms or slowing disease progression. The main disadvantage is the high risk and uncertainty associated with cell therapy development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as ProKidney is pre-revenue. Growth will depend on successful clinical development and commercialization of REN-001.
Future Projections: Future projections depend heavily on REN-001 clinical trial outcomes and regulatory approval. Analyst estimates vary widely, reflecting the inherent uncertainty of drug development.
Recent Initiatives: Recent initiatives include enrolling patients in Phase 3 clinical trials of REN-001 and securing additional funding.
Summary
ProKidney is a high-risk, high-reward company pursuing a novel approach to treating chronic kidney disease. Its success hinges on positive clinical trial outcomes for REN-001. The company has a strong scientific foundation and experienced management but faces significant regulatory and financial hurdles. Investors should monitor clinical trial progress and cash burn closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProKidney Corp.
Exchange NASDAQ | Headquaters Winston-Salem, NC, United States | ||
IPO Launch date 2022-07-12 | CEO & Director Dr. Bruce Culleton M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 204 | Website https://prokidney.com |
Full time employees 204 | Website https://prokidney.com | ||
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.